{
  "id": 914276,
  "title": "Third Rock Ventures V, L.P. director sells $7.4m Septerna shares",
  "url": "https://urgent.news/2026/08/14/third-rock-ventures-v-l-p-director-sells-7-4m-septerna-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T22:16:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/third-rock-ventures-v-lp-director-sells-74m-septerna-shares-93CH-4861608"
  },
  "original_language": "en",
  "account": "Third Rock Ventures V, L.P., a 10% owner and director of Septerna Inc. (NASDAQ:SEPN), sold 147,200 shares of the company's common stock on August 12, 2026, for around $7.4 million. The trades were carried out under a pre-set Rule 10b5-1 trading plan and occurred when Septerna's shares reached a 52-week high of $51.10. Selling at prices between $50.27 and $51.08, the transactions included 147,059 shares at an average of $50.27 per share, and an additional 141 shares at $51.08 per share. This sale reduced Third Rock Ventures V's direct holding of Septerna shares to 6,068,391. Meanwhile, Third Rock Ventures VI, L.P. indirectly owns 4,211,659 shares of the company. H.C. Wainwright and Stifel raised Septerna's price targets, citing progress in their Phase 1 trial of SEP-479, a treatment for hypoparathyroidism. Guggenheim also increased its target but later lowered it due to competitive pressures. Despite recent setbacks, Septerna's ongoing trials and developments have positively influenced analysts' outlooks.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}